· 供应链分析
涉及标的： $AAOI$AEHR$AVGO$JBL$LITE$MRVL$SIVE
光子学“超级周期”有许多细微的架构变化。如果你在去年错过了$LITE，今年可以通过CPO/激光来抢先布局下一个周期。$SIVE是我相对小众的激光敞口标的。他们参与在$JBL的1.6T LRO、$MRVL的Celestial、O-Net到超大规模业者。这对于一家市值约3.5亿美元的公司来说极为罕见。如果要我类比：类似于$AAOI在2025年的情况，或现在的$AEHR——正处于批量生产前的资质认证周期。正因如此，散户只看今天财务数据（负eps或capex支出）时会误解公司情况。而且与批量生产/capex支出相关的dfb激光扩产执行不确定性，已通过Win Semi被去风险化。然而看起来从2026年下半年开始会持续爬坡到2029年以后。可能在时间上稍早一些……但我认为这是对未来即将到来的趋势的一个不错研判。稀释是真实风险。但很多担忧已经被定价到约3.5亿美元市值里，尤其当$AVGO或AlChip这样的公司可以收购$SIVE用于垂直整合或干扰Marvell的CPO计划时。
There's many nuanced architectural changes for "supercycles" in photonics. If you feel like you missed $LITE from last year, just frontrun the next cycle with CPO / lasers. $SIVE was my lesser known pick for laser exposure. They're in $JBL 1.6T LRO, $MRVL via Celestial, O-Net -> Hyperscalers. Which is extremely abnormal for a ~$350M MC company. If I had to draw parallels: it's similar to $AAOI 2025 or $AEHR now with current qualification cycles before volume. Which is why retail misunderstands it when you look at purely financial numbers today with negative eps or capex spend. And a lot of that execution uncertainty with volume production / capex spend for scaling dfb laser is de-risked from Win Semi. However, it looks to just keep ramping past 2029+ starting from H2 2026. Might be a little early... But I think it's a decent read on what's up and coming. Dilution is a real risk. But a lot of fears are priced into its ~$350M MC, especially when a company like $AVGO or AlChip can just buy $SIVE for vertical integration or to troll Marvell’s CPO program.